Most Read News

EBITDA jumped 172% to ₹105 crore during the quarter. This is up from ₹39 crore a year ago.

Earlier this month, it had received a much larger contract valued at ₹105 crore for the supply of defence-grade explosives to overseas clients.

The EBITDA margin expanded to 10.5% from 6.5% in the corresponding quarter last year.

Operating performance was particularly robust. EBITDA for the quarter stood at ₹1,961 crore.

At around 12.53 PM, Orchid Pharma was trading 5% higher at ₹740.40, against the previous close of ₹705.15 on NSE.

The bank’s net interest income (NII) increased by 12.6%. The NII have reached ₹625 crore in Q1FY26.

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

Net profit also rose 20% year-on-year to ₹157 crore, largely helped by a strong jump in other income, which increased to ₹236 crore from ₹143 crore in the same quarter last year.

For the quarter ended June 30, 2025, Aster reported a consolidated revenue of ₹1,078 crore. This is up 8% from ₹1,002 crore in the same period last year.

ICICI Bank hits 52-week high in Sensex. TCS hits 52-week low in Sensex.